JP5646320B2 - 遺伝子発現と疼痛 - Google Patents

遺伝子発現と疼痛 Download PDF

Info

Publication number
JP5646320B2
JP5646320B2 JP2010507728A JP2010507728A JP5646320B2 JP 5646320 B2 JP5646320 B2 JP 5646320B2 JP 2010507728 A JP2010507728 A JP 2010507728A JP 2010507728 A JP2010507728 A JP 2010507728A JP 5646320 B2 JP5646320 B2 JP 5646320B2
Authority
JP
Japan
Prior art keywords
nucleotide
seq
oligonucleotide
sequence
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010507728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526541A (ja
JP2010526541A5 (enExample
Inventor
ジュリアン マメ，
ジュリアン マメ，
Original Assignee
アダイニクス， インコーポレイテッド
アダイニクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アダイニクス， インコーポレイテッド, アダイニクス， インコーポレイテッド filed Critical アダイニクス， インコーポレイテッド
Publication of JP2010526541A publication Critical patent/JP2010526541A/ja
Publication of JP2010526541A5 publication Critical patent/JP2010526541A5/ja
Application granted granted Critical
Publication of JP5646320B2 publication Critical patent/JP5646320B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
JP2010507728A 2007-05-11 2008-05-12 遺伝子発現と疼痛 Expired - Fee Related JP5646320B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91758307P 2007-05-11 2007-05-11
US60/917,583 2007-05-11
PCT/US2008/063471 WO2008141308A2 (en) 2007-05-11 2008-05-12 Gene expression and pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014149516A Division JP5890869B2 (ja) 2007-05-11 2014-07-23 遺伝子発現と疼痛

Publications (3)

Publication Number Publication Date
JP2010526541A JP2010526541A (ja) 2010-08-05
JP2010526541A5 JP2010526541A5 (enExample) 2012-04-05
JP5646320B2 true JP5646320B2 (ja) 2014-12-24

Family

ID=40002879

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2010507728A Expired - Fee Related JP5646320B2 (ja) 2007-05-11 2008-05-12 遺伝子発現と疼痛
JP2014149516A Expired - Fee Related JP5890869B2 (ja) 2007-05-11 2014-07-23 遺伝子発現と疼痛
JP2015207655A Expired - Fee Related JP6082796B2 (ja) 2007-05-11 2015-10-22 遺伝子発現と疼痛
JP2016064037A Expired - Fee Related JP6306075B2 (ja) 2007-05-11 2016-03-28 遺伝子発現と疼痛
JP2017106521A Pending JP2017148074A (ja) 2007-05-11 2017-05-30 遺伝子発現と疼痛

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014149516A Expired - Fee Related JP5890869B2 (ja) 2007-05-11 2014-07-23 遺伝子発現と疼痛
JP2015207655A Expired - Fee Related JP6082796B2 (ja) 2007-05-11 2015-10-22 遺伝子発現と疼痛
JP2016064037A Expired - Fee Related JP6306075B2 (ja) 2007-05-11 2016-03-28 遺伝子発現と疼痛
JP2017106521A Pending JP2017148074A (ja) 2007-05-11 2017-05-30 遺伝子発現と疼痛

Country Status (13)

Country Link
US (5) US7943591B2 (enExample)
EP (3) EP3199635B1 (enExample)
JP (5) JP5646320B2 (enExample)
AU (1) AU2008251320B2 (enExample)
CA (1) CA2723672C (enExample)
DK (1) DK2158316T3 (enExample)
ES (2) ES2542511T3 (enExample)
HR (1) HRP20150759T1 (enExample)
HU (1) HUE025701T2 (enExample)
PL (1) PL2158316T3 (enExample)
PT (1) PT2158316E (enExample)
SI (1) SI2158316T1 (enExample)
WO (1) WO2008141308A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3199635B1 (en) * 2007-05-11 2019-02-06 Adynxx, Inc. Gene expression and pain
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
US8609617B2 (en) 2009-09-04 2013-12-17 University Of Miami KLF family members regulate intrinsic axon regeneration ability
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
CA2848740A1 (en) 2011-09-16 2013-03-21 Mingxing Wang Amphiphilic cationic polymers for the delivery of therapeutic agents
US9139829B2 (en) * 2012-02-28 2015-09-22 Medical Diagnostic Laboratories, Llc SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment
CN104487096B (zh) * 2012-05-10 2020-09-15 埃迪恩克斯股份有限公司 用于活性成分递送的配制物
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
CN112007045B (zh) 2012-07-13 2026-01-06 波涛生命科学有限公司 手性控制
JP6246121B2 (ja) 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
GB201310853D0 (en) * 2013-06-18 2013-07-31 Ucb Pharma Sa Method
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
AU2015301491A1 (en) * 2014-08-15 2017-02-02 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
ES2912176T3 (es) * 2015-09-09 2022-05-24 Anges Inc Señuelo quimérico
US20200017853A1 (en) * 2016-02-29 2020-01-16 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression
US20260078376A1 (en) * 2022-08-26 2026-03-19 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US5206152A (en) * 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5272056A (en) 1991-01-03 1993-12-21 The Research Foundation Of State University Of New York Modification of DNA and oligonucleotides using metal complexes of polyaza ligands
EP0580754A1 (en) * 1991-04-18 1994-02-02 The Salk Institute For Biological Studies Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
WO1995004064A1 (en) * 1993-07-29 1995-02-09 The Regents Of The University Of California Polynucleotide decoys that ihnibit mhc-ii expression and uses thereof
EP0732929B1 (en) * 1993-10-29 2008-05-14 The Brigham And Women's Hospital, Inc. Therapeutic use of cis-element decoys in vivo
US6034234A (en) 1994-11-17 2000-03-07 Taiho Pharmaceutical Co., Ltd. Double-stranded oligonucleotide and anticancer agent containing the same as active ingredient
WO1996029433A1 (en) 1995-03-23 1996-09-26 Research Foundation Of State University Of New York Rest protein and dna
DK0824588T3 (da) * 1995-05-11 2004-08-16 Applied Research Systems Inhibitor af IL-6 aktivitet
DE69636997T2 (de) * 1995-05-12 2007-07-12 Anges MG Inc., Ibaraki HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN
GB9515356D0 (en) 1995-07-26 1995-09-20 Medical Res Council Improvements in or relating to delivery of nucleic acid
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
AU737926B2 (en) * 1996-05-20 2001-09-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligonucleotides which specifically bind retroviral nucleocapsid proteins
US6022863A (en) * 1996-05-21 2000-02-08 Yale University Regulation of gene expression
JP4215219B2 (ja) * 1997-07-04 2009-01-28 アンジェスＭｇ株式会社 脳保護剤
JP3667047B2 (ja) 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6060310A (en) * 1997-11-24 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Transcription factor decoy and tumor growth inhibitor
AU1656299A (en) 1997-12-16 1999-07-05 University Of Saskatchewan Conductive metal-containing nucleic acids
PL345207A1 (en) 1998-06-02 2001-12-03 Glaxo Group Ltd Gene therapy method
US6818626B1 (en) 1998-07-17 2004-11-16 Mirus Corporation Chelating systems for use in the delivery of compounds to cells
US6867289B1 (en) * 1998-10-26 2005-03-15 Board Of Regents, The University Of Texas Systems Thio-modified aptamer synthetic methods and compositions
US6008048A (en) * 1998-12-04 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of EGR-1 expression
US7160869B2 (en) 1998-12-16 2007-01-09 University Of Saskatchewan Biologically active metal-containing nucleic acids
EP1141366B1 (en) 1998-12-23 2007-02-21 Genentech, Inc. Transfectacons comprising calcium phosphate and a nucleic acid
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6333408B1 (en) * 1999-03-08 2001-12-25 Kureha Chemical Industry Co., Ltd. Oligonucleotides inhibitors of PAI-1 MRNA
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
CA2300328A1 (en) * 1999-09-14 2001-03-14 Cardiogene Gentherap. Systeme Ag Modulating transcription of genes in vascular cells
US6927027B2 (en) 1999-12-21 2005-08-09 Ingeneus Corporation Nucleic acid multiplex formation
US6969704B1 (en) * 2000-08-25 2005-11-29 The Trustees Of Columbia University In The City Of New York Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
DE10049549A1 (de) * 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
CA2462081A1 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
AU2001292310A1 (en) 2000-11-24 2002-06-03 Chugai Seiyaku Kabushiki Kaisha Method of regulating the activity of expression product of gene transferred intoliving body
WO2002066071A2 (en) 2001-01-03 2002-08-29 Thomas Jefferson University Treatment of tissue fibrosis by blocking the sp1 transcription factor
US7060690B2 (en) * 2001-01-22 2006-06-13 Genta Incorporated Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof
DE60225899T2 (de) 2001-02-20 2009-04-09 AnGes MG Inc., Ibaraki-shi TOPISCHE ANWENDUNG EINES NF-kB DECOYS ZUR BEHANDLUNG ATOPISCHER DERMATITIS
AU2002254132A1 (en) 2001-03-06 2002-09-19 Sierra Sciences, Inc. Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
US20030166555A1 (en) * 2001-04-02 2003-09-04 Alberini Cristina M. Methods and compositions for regulating memory consolidation
EP1298141A1 (en) 2001-09-27 2003-04-02 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Interleukin-4 (IL-4) promoter sequences specifically interacting with IRF-1 and IRF-2
DE10148828B4 (de) * 2001-10-04 2005-05-19 Avontec Gmbh Modulation der Expression STAT-1-abhängiger Gene
US6663880B1 (en) 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
JP2005519917A (ja) 2002-02-01 2005-07-07 オメロス コーポレイション 軟骨分解の全身阻害のための組成物および方法
CN1240439C (zh) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
CA2483505A1 (en) 2002-04-26 2003-11-06 Anges Mg, Inc. Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
DE10242319A1 (de) * 2002-09-12 2004-03-25 Avontec Gmbh Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens
DE10257421A1 (de) * 2002-12-09 2004-07-08 Grünenthal GmbH Regulatorische Elemente im 5'-Bereich des VR1-Gens
KR20140148502A (ko) 2002-12-09 2014-12-31 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
JP2007528707A (ja) 2003-06-30 2007-10-18 マサチューセッツ インスティテュート オブ テクノロジー 統合失調症の診断および治療のための標的としてのｅｇｒ遺伝子
US20080233644A1 (en) * 2003-09-12 2008-09-25 Helen Fillmore Chimeric Transcription Factor Decoy Oligonucleotides
JP2005336081A (ja) 2004-05-26 2005-12-08 Anges Mg Inc Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
WO2006012625A2 (en) * 2004-07-22 2006-02-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Stat3 decoy oligonucleotides and uses therefor
AU2005286640A1 (en) * 2004-09-21 2006-03-30 Anesiva, Inc. Delivery of polynucleotides
AU2005288522B2 (en) 2004-09-28 2012-06-28 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
WO2006043722A1 (ja) * 2004-10-22 2006-04-27 Anges Mg, Inc. キメラ（ダブル）デコイ
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US8268572B2 (en) * 2005-03-04 2012-09-18 Dana-Farber Cancer Institute, Inc. Methods to identify inhibitors of Runx1-mediated expression of nociceptive receptors and ion channels
US7680060B2 (en) * 2005-03-08 2010-03-16 Cisco Technology, Inc. Transferring state information in a network
ATE524546T1 (de) * 2005-03-25 2011-09-15 Medtronic Inc Verwendung von anti-tnf oder anti-il1-rnai zur unterdrückung der wirkung entzündungsfördernder cytokine zur lokalen schmerzbehandlung
ES2845146T3 (es) 2006-10-09 2021-07-26 Neurofluidics Inc Sistema de purificación de líquido cefalorraquídeo
CA2682135A1 (en) 2007-04-17 2008-10-30 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
EP3199635B1 (en) 2007-05-11 2019-02-06 Adynxx, Inc. Gene expression and pain
KR20150039873A (ko) 2010-08-20 2015-04-13 레플리코르 인코포레이티드 올리고뉴클레오타이드 킬레이트 복합체
EP2723865B1 (en) 2011-06-21 2019-03-27 Alnylam Pharmaceuticals, Inc. METHODS FOR DETERMINING ACTIVITY OF RNAi IN A SUBJECT
EP3257505A1 (en) 2011-07-20 2017-12-20 Hospira, Inc. Compositions comprising diclofenac for the treatment of post-operative pain
CN104487096B (zh) 2012-05-10 2020-09-15 埃迪恩克斯股份有限公司 用于活性成分递送的配制物
CA2873529C (en) 2012-05-18 2020-08-18 Replicor Inc. Oligonucleotide chelate complex-polypeptide compositions and methods
AU2015301491A1 (en) 2014-08-15 2017-02-02 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
US20200017853A1 (en) 2016-02-29 2020-01-16 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression

Also Published As

Publication number Publication date
US8093225B2 (en) 2012-01-10
WO2008141308A2 (en) 2008-11-20
EP2818550B1 (en) 2016-12-28
HK1205530A1 (en) 2015-12-18
JP6082796B2 (ja) 2017-02-15
ES2619314T3 (es) 2017-06-26
EP2818550A1 (en) 2014-12-31
JP2017148074A (ja) 2017-08-31
US20120232131A1 (en) 2012-09-13
HUE025701T2 (en) 2016-04-28
EP2158316B1 (en) 2015-04-15
JP2010526541A (ja) 2010-08-05
US8741864B2 (en) 2014-06-03
DK2158316T3 (en) 2015-07-20
WO2008141308A3 (en) 2009-03-05
US20110166212A1 (en) 2011-07-07
JP5890869B2 (ja) 2016-03-22
US9290762B2 (en) 2016-03-22
AU2008251320A1 (en) 2008-11-20
JP2014198053A (ja) 2014-10-23
US20140343132A1 (en) 2014-11-20
AU2008251320B2 (en) 2013-12-19
ES2542511T3 (es) 2015-08-06
HRP20150759T1 (hr) 2015-08-14
US20080300209A1 (en) 2008-12-04
EP3199635B1 (en) 2019-02-06
US7943591B2 (en) 2011-05-17
EP2158316A4 (en) 2011-11-09
CA2723672C (en) 2019-09-03
CA2723672A1 (en) 2008-11-20
EP2158316A2 (en) 2010-03-03
US10041069B2 (en) 2018-08-07
PT2158316E (pt) 2015-07-20
JP6306075B2 (ja) 2018-04-04
JP2016117775A (ja) 2016-06-30
PL2158316T3 (pl) 2015-10-30
US20160222382A1 (en) 2016-08-04
SI2158316T1 (sl) 2015-08-31
EP3199635A1 (en) 2017-08-02
JP2016014070A (ja) 2016-01-28

Similar Documents

Publication Publication Date Title
JP6306075B2 (ja) 遺伝子発現と疼痛
JP7687682B2 (ja) 筋疾患治療用医薬組成物
JP7049249B2 (ja) 中枢神経系疾患の処置のための組成物および方法
EA022429B1 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ β-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
CA2775111A1 (en) Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
JP6705807B2 (ja) 疼痛を治療するためのオリゴヌクレオチドデコイ
CN104487096B (zh) 用于活性成分递送的配制物
AU2014201462B2 (en) Gene expression and pain
AU2016266076B2 (en) Gene expression and pain
US20220348916A1 (en) Composition for diagnosis or treatment of a condition associated with increased activity of eif4e comprising an eif4e inhibitor
HK1205530B (en) Gene expression and pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130510

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130809

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140723

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141014

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141105

R150 Certificate of patent or registration of utility model

Ref document number: 5646320

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees